Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Public ClinicalTrials.gov record NCT01127451. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether participants with Stage IIIC and Stage IV Melanoma experience benefit when treated with Denileukin diftitox in two different dosing schedules.
Study identification
- NCT ID
- NCT01127451
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 21, 2010
- Primary completion
- Apr 6, 2015
- Completion
- Apr 6, 2015
- Last update posted
- Apr 12, 2022
2010 – 2015
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Encinitas | California | 92008 | — |
| Not listed | Los Angeles | California | 90025 | — |
| Not listed | Washington D.C. | District of Columbia | 20010 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | Baltimore | Maryland | 21237 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Lincoln | Nebraska | 68510 | — |
| Not listed | Portland | Oregon | 97227 | — |
| Not listed | Amarillo | Texas | 79106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01127451, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2022 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01127451 live on ClinicalTrials.gov.